{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:45:02Z","timestamp":1762674302069,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-123265"],"award-info":[{"award-number":["MOP-123265"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bone.2019.01.028","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:50:28Z","timestamp":1549021828000},"page":"232-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy"],"prefix":"10.1016","volume":"121","author":[{"given":"Sung-Hee","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Grynpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-7490","authenticated-orcid":false,"given":"Jane","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2019.01.028_bb0005","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2019.01.028_bb0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","article-title":"Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England","volume":"20","author":"Van Ruiten","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.bone.2019.01.028_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.bone.2019.01.028_bb0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-003-1443-y","article-title":"Bone mineral density and bone metabolism in Duchenne muscular dystrophy","volume":"14","author":"Bianchi","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.01.028_bb0025","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.410","article-title":"Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans","volume":"26","author":"Rufo","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/mus.26195","article-title":"Altered bone-regulating myokine expression in skeletal muscle of Duchenne muscular dystrophy mouse models","volume":"58","author":"Zhou","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bone.2019.01.028_bb0035","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1006\/cyto.2000.0747","article-title":"gp130 cytokine family and bone cells","volume":"12","author":"Heymann","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.bone.2019.01.028_bb0040","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprogerin\/osteogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2019.01.028_bb0045","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"5","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2019.01.028_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clin. Pediatr."},{"key":"10.1016\/j.bone.2019.01.028_bb0055","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bone.2019.01.028_bb0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bone.2019.01.028_bb0065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bone.2016.06.015","article-title":"Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy","volume":"90","author":"Yoon","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.01.028_bb0070","article-title":"Pre-treatment with pamidronate improves bone mechanical properties in Mdx mice treated with glucocorticoids","author":"Chen","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2019.01.028_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tem.2015.01.004","article-title":"Anabolic effects of PTH and the \u2018anabolic window\u2019","volume":"26","author":"Pazianas","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bone.2019.01.028_bb0080","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2019.01.028_bb0085","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.01.028_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10974-015-9406-4","article-title":"What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of the disease?","volume":"36","author":"Manning","year":"2015","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.bone.2019.01.028_bb0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2010.12.002","article-title":"Bone is functionally impaired in dystrophic mice but less so that skeletal muscle","volume":"21","author":"Novotny","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2019.01.028_bb0100","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bone.2005.05.008","article-title":"Polychrome labeling of bone with seven different fluorochromes: enhancing discrimination by spectral image analysis","volume":"37","author":"Pautke","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.01.028_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histochemistry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0115","series-title":"Quantitative Determination of Muscle Fiber Diameter (Minimal Feret's Diameter) and Percentage of Centralized Nuclei","first-page":"1","author":"Dubach-Powell","year":"2014"},{"key":"10.1016\/j.bone.2019.01.028_bb0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jcp.55.5.375","article-title":"Validation of a simple, rapid, and economical technique for distinguishing type 1 and 2 fibres in fixed and frozen skeletal muscle","volume":"55","author":"Behan","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bone.2019.01.028_bb0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00270046","article-title":"Fibres of intermediate type 1C and 2C are found continuously in mdx soleus muscle up to 52 weeks","volume":"100","author":"Pastoret","year":"1993","journal-title":"Histochemistry"},{"key":"10.1016\/j.bone.2019.01.028_bb0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0883073816650034","article-title":"Fracture in Duchenne muscular dystrophy: natural history and vitamin D deficiency","volume":"31","author":"Perera","year":"2016","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.bone.2019.01.028_bb0135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-010-1275-5","article-title":"Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment","volume":"22","author":"Bianchi","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2019.01.028_bb0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bone.2019.01.028_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fphys.2017.00426","article-title":"Site-specific variations in bone mineral density under systemic conditions inducing osteoporosis in minipigs","volume":"8","author":"Schulz","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bone.2019.01.028_bb0150","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0155","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/art.23954","article-title":"Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2019.01.028_bb0160","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/en.2009-1488","article-title":"Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice","volume":"151","author":"Weinstein","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2019.01.028_bb0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4077\/CJP.2014.BAC242","article-title":"Effect of intermittent administration of hPTH(1-34) on cortical bone geometry in rats treated with high-dose glucocorticoids","volume":"57","author":"Iwamoto","year":"2014","journal-title":"Chin. J. Phys."},{"key":"10.1016\/j.bone.2019.01.028_bb0170","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0175","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bone.2012.05.003","article-title":"Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice","volume":"51","author":"Gray","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2019.01.028_bb0180","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00223-009-9301-3","article-title":"Glucocorticoid-induced osteoporosis in growing mice is not prevented by simultaneous intermittent PTH treatment","volume":"85","author":"Postnov","year":"2009","journal-title":"Calcif. Tissue Int."},{"issue":"5066","key":"10.1016\/j.bone.2019.01.028_bb0185","article-title":"Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation","volume":"4","author":"Kimura","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2019.01.028_bb0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","article-title":"Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy","volume":"52","author":"Webster","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.bone.2019.01.028_bb0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jnr.490350403","article-title":"Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse","volume":"35","author":"Passaquin","year":"1993","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bone.2019.01.028_bb0200","first-page":"9","article-title":"Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy","volume":"31","author":"Angelini","year":"2012","journal-title":"Acta Myologica"},{"key":"10.1016\/j.bone.2019.01.028_bb0205","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0960-8966(02)00101-3","article-title":"Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research","volume":"12","author":"Muntoni","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2019.01.028_bb0210","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00198-016-3761-x","article-title":"Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report","volume":"27","author":"Catalano","year":"2016","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219300390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219300390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T17:43:45Z","timestamp":1565199825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219300390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":42,"alternative-id":["S8756328219300390"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.01.028","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}